This trial is evaluating whether Treatment will improve 2 primary outcomes in patients with Breast Cancer. Measurement will happen over the course of at 1 week (after second survey completed).
This trial requires 100 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"The authors summarize the published data concerning treatments of prostate cancer, including radiotherapy, hormonal therapy, chemotherapy and targeted therapies. They emphasize the need for more rigorous studies aimed at evaluating the efficacy of these different therapeutic approaches." - Anonymous Online Contributor
"Although many different therapies were analyzed, only two common treatments were identified – radical prostatectomy and radiotherapy. Radical prostatectomy was found to be the most frequently used treatment in 2011, despite its cumulative positive outcomes. Radiotherapy was found to be less frequently used than previously reported, but still remains the standard treatment for localized prostate cancer, particularly in younger and healthier men." - Anonymous Online Contributor
"Prostatic carcinoma can develop at any age. However, prostate cancer develops most commonly between ages 50 and 70 years. Men's risk of developing prostate cancer appears higher after the age of 40 years than before that time. A larger number of men begin to develop prostate cancer after their fiftieth birthday. As many as half of all men over age 70 will have prostate cancer sometime during their lives. The average interval between first diagnosis of prostate cancer and death from the disease is 6–8 years." - Anonymous Online Contributor
"We found no evidence that current treatments for BPH are ineffective. Although treatment does have some side effects, we found no evidence that those side effects are excessive compared to the risks associated with untreated disease. Furthermore, the treatment options available for BPH do not appear to be more effective than those available for symptomatic prostate cancer." - Anonymous Online Contributor
"Although this study only covers the period 2003-2008, it suggests that more than 830,000 men will be diagnosed with prostate cancer before they die in 2005, and more than 1.2 million men will be diagnosed before they die in 2007. This is more than double the number reported in 1960. Even though these numbers are based solely on deaths due to prostate cancer, they still suggest that almost 3 million men in the U.S. will be diagnosed with prostate cancer during the years 2006-2007. A significant proportion of these men will be diagnosed at an advanced stage where treatment options are limited. These statistics emphasize the need for earlier detection of prostate cancer, especially among men who are uninsured or underinsured." - Anonymous Online Contributor
"Improvements in surgical approaches, radiation therapy, chemotherapy and hormonal therapy have led to a sharp increase in overall survival in patients diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). Although many of these therapies do not provide complete resolution of cancer symptoms, they have increased the proportion of men who can expect to live longer than 10 years after diagnosis." - Anonymous Online Contributor
"The two treatments showed equivalent outcomes after radical prostatectomy in terms of the PSA-recurrence rate, biochemical progression, and overall survival. However, operative therapy was costlier than radiotherapy." - Anonymous Online Contributor
"In a recent study, less than half of the patients were treated surgically and only 32% of these men received adjuvant radiation therapy; yet, the cancer was confined to the prostate at radical surgery and to the prostate and seminal vesicles at radical surgery and/or radiation treatment." - Anonymous Online Contributor
"Despite 20 yr of clinical trial experience with active surveillance among all age groups, patients are still hesitant to enroll in such studies. They believe that more information about the risks and benefits is needed before they decide whether to take part in these studies. Further efforts to educate patients regarding the value of clinical trials will be important to encourage participation." - Anonymous Online Contributor
"Over the past decade, research efforts have focused on developing more effective treatments to control prostate cancer (e.g., targeting metastatic targets, inhibiting growth factors, and activating apoptotic pathways). Although most of these new therapies are still being developed, some of them are already being tested clinically. Notable examples of these agents include Trastuzumab, Oxaliplatin, and Zoledronic Acid. Despite advances in understanding the mechanisms of disease progression and therapy, the majority of patients do not respond to initial treatments and will eventually succumb to the disease." - Anonymous Online Contributor
"Data from a recent study suggest that radical prostatectomy combined with adjuvant radiotherapy for clinically localized PCa can achieve excellent survival rates compared with standard treatment options and should be offered to all eligible patients regardless of grade or stage." - Anonymous Online Contributor